Cargando…

Peritoneal dialysis as a treatment option in autosomal dominant polycystic kidney disease

PURPOSE: When choosing a dialysis option for ADPKD patients, peritoneal dialysis (PD) is often discouraged, due to its potential drawbacks: risk of abdominal hernias and dialysis fluid leaks, risk of peritonitis and insufficient dialysis adequacy. The present study was designed to compare the outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Jankowska, Magdalena, Chmielewski, Michał, Lichodziejewska-Niemierko, Monika, Jagodziński, Piotr, Rutkowski, Bolesław
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600724/
https://www.ncbi.nlm.nih.gov/pubmed/26282281
http://dx.doi.org/10.1007/s11255-015-1087-9
_version_ 1782394459494809600
author Jankowska, Magdalena
Chmielewski, Michał
Lichodziejewska-Niemierko, Monika
Jagodziński, Piotr
Rutkowski, Bolesław
author_facet Jankowska, Magdalena
Chmielewski, Michał
Lichodziejewska-Niemierko, Monika
Jagodziński, Piotr
Rutkowski, Bolesław
author_sort Jankowska, Magdalena
collection PubMed
description PURPOSE: When choosing a dialysis option for ADPKD patients, peritoneal dialysis (PD) is often discouraged, due to its potential drawbacks: risk of abdominal hernias and dialysis fluid leaks, risk of peritonitis and insufficient dialysis adequacy. The present study was designed to compare the outcomes and dialysis efficacy in ADPKD patients treated with PD, in comparison with non-ADPKD subjects. METHODS: This study was a retrospective analysis of the data from the national PD registry in which 106 ADPKD and 1606 non-ADPKD incident PD patients were evaluated. Data on dialysis adequacy, risk of dialysis-associated complications, as well as patient and technique survival were compared between the groups. RESULTS: The ADPKD patients did not differ from the non-ADPKD controls in terms of dialysis adequacy. After a median observation time of 32 months, there were no differences in patient or technique survival. The risk of abdominal hernias and dialysis fluid leaks was twice as high in ADPKD subjects, compared to the non-ADPKD group. However, these complications did not result in a need for a permanent transfer to hemodialysis. CONCLUSIONS: Dialysis adequacy, and patient and technique survival are similar in the ADPKD and non-ADPKD patients treated with PD. PD seems a feasible treatment option for end-stage renal failure in the course of ADPKD.
format Online
Article
Text
id pubmed-4600724
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-46007242015-10-16 Peritoneal dialysis as a treatment option in autosomal dominant polycystic kidney disease Jankowska, Magdalena Chmielewski, Michał Lichodziejewska-Niemierko, Monika Jagodziński, Piotr Rutkowski, Bolesław Int Urol Nephrol Nephrology - Original article PURPOSE: When choosing a dialysis option for ADPKD patients, peritoneal dialysis (PD) is often discouraged, due to its potential drawbacks: risk of abdominal hernias and dialysis fluid leaks, risk of peritonitis and insufficient dialysis adequacy. The present study was designed to compare the outcomes and dialysis efficacy in ADPKD patients treated with PD, in comparison with non-ADPKD subjects. METHODS: This study was a retrospective analysis of the data from the national PD registry in which 106 ADPKD and 1606 non-ADPKD incident PD patients were evaluated. Data on dialysis adequacy, risk of dialysis-associated complications, as well as patient and technique survival were compared between the groups. RESULTS: The ADPKD patients did not differ from the non-ADPKD controls in terms of dialysis adequacy. After a median observation time of 32 months, there were no differences in patient or technique survival. The risk of abdominal hernias and dialysis fluid leaks was twice as high in ADPKD subjects, compared to the non-ADPKD group. However, these complications did not result in a need for a permanent transfer to hemodialysis. CONCLUSIONS: Dialysis adequacy, and patient and technique survival are similar in the ADPKD and non-ADPKD patients treated with PD. PD seems a feasible treatment option for end-stage renal failure in the course of ADPKD. Springer Netherlands 2015-08-19 2015 /pmc/articles/PMC4600724/ /pubmed/26282281 http://dx.doi.org/10.1007/s11255-015-1087-9 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Nephrology - Original article
Jankowska, Magdalena
Chmielewski, Michał
Lichodziejewska-Niemierko, Monika
Jagodziński, Piotr
Rutkowski, Bolesław
Peritoneal dialysis as a treatment option in autosomal dominant polycystic kidney disease
title Peritoneal dialysis as a treatment option in autosomal dominant polycystic kidney disease
title_full Peritoneal dialysis as a treatment option in autosomal dominant polycystic kidney disease
title_fullStr Peritoneal dialysis as a treatment option in autosomal dominant polycystic kidney disease
title_full_unstemmed Peritoneal dialysis as a treatment option in autosomal dominant polycystic kidney disease
title_short Peritoneal dialysis as a treatment option in autosomal dominant polycystic kidney disease
title_sort peritoneal dialysis as a treatment option in autosomal dominant polycystic kidney disease
topic Nephrology - Original article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600724/
https://www.ncbi.nlm.nih.gov/pubmed/26282281
http://dx.doi.org/10.1007/s11255-015-1087-9
work_keys_str_mv AT jankowskamagdalena peritonealdialysisasatreatmentoptioninautosomaldominantpolycystickidneydisease
AT chmielewskimichał peritonealdialysisasatreatmentoptioninautosomaldominantpolycystickidneydisease
AT lichodziejewskaniemierkomonika peritonealdialysisasatreatmentoptioninautosomaldominantpolycystickidneydisease
AT jagodzinskipiotr peritonealdialysisasatreatmentoptioninautosomaldominantpolycystickidneydisease
AT rutkowskibolesław peritonealdialysisasatreatmentoptioninautosomaldominantpolycystickidneydisease